Logo Image
|Articles|April 9, 2021

Parenteral Drug Association (PDA)

PDA is the leading global provider of science, technology, regulatory information, and education for the biopharmaceutical community. For 75 years, PDA has developed sound, practical information and resources to advance science and regulation through the expertise of our global membership. We promote dialogue on new technology and regulations to ensure high-quality pharmaceutical products. PDA offers conferences, workshops, training courses, and a wide range of technical resources to help you improve your processes and advance your career.

Parenteral Drug Association (PDA)
4350 East West Hwy, Suite 600
Bethesda, MD 20814 info@pda.org
www.pda.org
Tel. 301.656.5900

Related to this article

View more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more